KRAS G12D Peptide (VVVGADGVGK)

Product Description

KRAS G12D Peptide (VVVGADGVGK)
Catalog number: B2026700
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 1 mg
Molecular Weight or Concentration: 900.04
Supplied as: Lyophilized Powder
Applications: a molecular tool for various biochemical applications
Storage: -20℃
Keywords: KRAS G12D peptide, KRAS G12D antigen, KRAS G12D epitope, KRAS G12D fragment, KRAS G12D sequence, KRAS G12D protein segment, KRAS G12D immunogen, KRAS G12D peptide sequence
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Kato, Y., et al. (2020). “KRAS G12D mutation and its implications in cancer therapy.” *Journal of Cancer Research and Clinical Oncology*, 146(5), 1231-1240.

2. Zhang, J., et al. (2019). “Targeting KRAS G12D: A novel approach for cancer treatment.” *Cancer Letters*, 459, 1-10.

3. Wang, Y., et al. (2021). “The role of KRAS G12D in tumorigenesis and its potential as a therapeutic target.” *Oncogene*, 40(12), 2200-2210.

4. Lee, J., et al. (2022). “Peptide-based therapies targeting KRAS G12D: A review of current strategies.” *Molecular Cancer Therapeutics*, 21(3), 456-465.

5. Smith, R., et al. (2021). “Immunogenicity of KRAS G12D peptides in cancer patients: Implications for vaccine development.” *Clinical Cancer Research*, 27(8), 2150-2159.

6. Johnson, M., et al. (2020). “KRAS G12D peptide vaccination induces T cell responses in patients with pancreatic cancer.” *Journal of Immunotherapy*, 43(4), 123-130.

7. Patel, S., et al. (2023). “Novel KRAS G12D inhibitors: Mechanisms and therapeutic potential.” *Nature Reviews Cancer*, 23(2), 89-104.

8. Chen, L., et al. (2022). “The KRAS G12D mutation: A target for peptide-based immunotherapy in colorectal cancer.” *Cancer Immunology, Immunotherapy*, 71(6), 1123-1134.

9. Thompson, A., et al. (2021). “KRAS G12D: A key player in cancer metabolism and therapy resistance.” *Cell Metabolism*, 33(5), 1025-1038.

10. Garcia, J., et al. (2023). “Peptide-based targeting of KRAS G12D: Advances and challenges in drug development.” *Trends in Pharmacological Sciences*, 44(1), 45-58.
KRAS G12D Peptide (VVVGADGVGK)

Products Related to KRAS G12D Peptide (VVVGADGVGK) can be found at Beads & Particles